Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NanoViricides, Inc. Common Stock (NY: NNVC )

1.210 -0.020 (-1.63%)
Official Closing Price Updated: 8:00 PM EDT, Mar 13, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NanoViricides, Inc. Common Stock

< Previous 1 2 3 4 5 6 7 Next >
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
By David Willey, Benzinga 
Via TheNewswire.com
Exposures COVID-19
Why Better Therapeutics Are Trading Higher By 51%; Here Are 20 Stocks Moving Premarket
Gainers CytoMed Therapeutics Limited (NASDAQ: GDTC) shares surged 109.2% to $7.30 in pre-market trading after gaining 9% on Monday. 
Via Benzinga
Company’s Broad-Spectrum Antiviral NV-387 Has Demonstrated Excellent Effectiveness in RSV in a Lethal Lung Disease Animal Model, Reports NanoViricides
Via ACCESSWIRE
Novel Nanomedicine Platform With Pipeline Of Antivirals Goes To Human Trials – What Other Viruses Could This COVID Treatment Target?
Read the latest report on NanoViricides here. 
Via Benzinga
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
By David Willey, Benzinga 
Via TheNewswire.com
Exposures COVID-19
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment 
Via News Direct
Exposures COVID-19
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
By David Willey, Benzinga 
Via TheNewswire.com
Exposures COVID-19
Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs
Via ACCESSWIRE
NanoViricides Inc. (NYSE American: NNVC) Begins Long-Awaited Clinical Trials For Its Anti-Viral Nanomedicine NV-CoV-2, Oral, Amid Continuing Need For COVID Treatment
Read the latest report on NanoViricides here. 
Via Benzinga
NanoViricides Announces that Clinical Trials of Its Broad-Spectrum Antiviral Drug NV-CoV-2 Have Begun
Via ACCESSWIRE
The 7 Most Promising Penny Stocks to Buy in June
These top penny stocks for June look to have legitimate catalysts that can certainly send share prices higher. 
Via InvestorPlace
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NanoViricides, Inc. to Present at the BIO International Convention in Boston on June 5th, 2023 at 3:15pm ET
Via ACCESSWIRE
NanoViricides Has Filed its Quarterly Report - Clinical Trials of Broad-Spectrum COVID Drug About to Begin
Via ACCESSWIRE
TechMediaBreaks – NanoViricides Inc. (NYSE American: NNVC) Slated to Participate at Inaugural Ef Hutton Global Conference
Via Investor Brand Network
Exposures COVID-19
NanoViricides, Inc. (NYSE American: NNVC) Featured in Coverage of the Inaugural EF Hutton Global Conference
Via Investor Brand Network
Exposures COVID-19
NanoViricides is Expanding its Broad-Spectrum Antiviral Program to Explore Further Antiviral Applications of its COVID Clinical Drug Ingredient
Via ACCESSWIRE
NanoViricides Has Shipped Drug Products for Impending Clinical Trials of NV-CoV-2, Its COVID Drug Candidate
Via ACCESSWIRE
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
NanoViricides Signs a License Agreement That Includes Clinical Evaluation of Its COVID-19 Drug Candidates
Via ACCESSWIRE
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All
COVID Remains A Global Threat – NanoViricides Set To Begin Clinical Trials For Pan-Coronavirus Drug To Help Defeat COVID Once And For All 
Via News Direct
Exposures COVID-19
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats 
Via News Direct
Topics Death Economy
Exposures COVID-19 Death Economy
A Company With Solutions Against Emerging COVID Variants And Other Viral Infections To Combat Future Pandemic Threats
By Ernest Dela Aglanu, Benzinga 
Via TheNewswire.com
Topics Death Economy
Exposures COVID-19 Death Economy
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It 
Via News Direct
Topics Death
Exposures COVID-19 Death
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It
By Ernest Dela Aglanu, Benzinga 
Via TheNewswire.com
Topics Death
Exposures COVID-19 Death
With Nearly 20,000 Americans Still Hospitalized, COVID Remains A Threat – NanoViricides Gets Ready To Begin Clinical Trials For The World To Defeat It, And To Prepare For Battling Against The Next Likely Coronavirus Pandemic
Read the latest report on NanoViricides, Inc (NYSE: NNVC) here. 
Via Benzinga
uniQure To Rally Around 162%? Here Are 10 Other Analyst Forecasts For Tuesday
UBS cut the price target for Honeywell International Inc. (NASDAQ: HON) from $193 to $185. UBS analyst Chris Snyder maintained a Sell rating. Honeywell shares fell 0.2% to $191.99 in pre-market... 
Via Benzinga
NanoViricides Has Filed its Quarterly Report - Company has Begun Production of Coronavirus Drug for Clinical Trials
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS